Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 75 publications
XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant pancreatic ductal adenocarcinoma.
Journal: Cancer letters
Published: March 02, 2026
Genomic and Transcriptomic Landscapes of MEN1-Wild-Type Low-Grade Metastatic Pancreatic NETs Uncover Key Oncogenic Drivers and Targetable Pathways.
Journal: bioRxiv : the preprint server for biology
Published: January 23, 2026
PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer.
Journal: bioRxiv : the preprint server for biology
Published: December 22, 2025
TGFBR1*6A and Risk for Colorectal Cancer.
Journal: Cancer communications (London, England)
Published: December 15, 2025
Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcinoma.
Journal: bioRxiv : the preprint server for biology
Published: December 15, 2025
Corrigendum to-"Ca2+ and CACNA1H mediate targeted suppression of breast cancer brain metastasis by AM RF EMF"-[eBiomedicine, 44 (2019) 194-208].
Journal: EBioMedicine
Published: December 28, 2024
Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges.
Journal: Signal transduction and targeted therapy
Published: December 23, 2024
Editor's Note: Truncated Glioma-Associated Oncogene Homolog 1 (tGLI1) Mediates Mesenchymal Glioblastoma via Transcriptional Activation of CD44.
Journal: Cancer research
Published: August 12, 2024
Multiomic Characterization of RCC1 and RCC2 Expression and Their Association With Molecular Alterations, Immune Phenotypes, and Cancer Outcomes.
Journal: JCO oncology advances
Published: June 19, 2024
Targeting guanine nucleotide exchange factors for novel cancer drug discovery.
Journal: Expert opinion on drug discovery
Published: June 17, 2024
Last Updated: 09/26/2026